MedDataX Logo

Machine Learning for Recurrence Risk of Pancreatic Cancer After Radical Resection

NCT ID: NCT05589480

Last Updated: 2023-12-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

226 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-08-01

Study Completion Date

2022-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Recurrence of Pancreatic Cancer(PCa) is a multifactorial event. Based on the clinicopathological characteristics and imaging data of patients with PCa, the investigators used image processing and machine learning algorithms to build a more comprehensive and robust model, and added some unused features to explore its clinical application value.

A retrospective analysis of patients with PCa who underwent radical resection at Zhejiang Cancer Hospital (Hangzhou, China) from January 2013 to December 2020. The database was extracted from the preoperative demographics, blood markers, and surgical pathology information of patients undergoing radical PCa surgery in the investigators' hospital. The investigators used the PyRadiomics platform to extract image features.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

postoperative recurrence

preoperative demographics, blood markers, surgical pathology information，and enhanced CT features.

Intervention Type OTHER

preoperative demographics, blood markers, surgical pathology information，and enhanced CT features.

postoperative non-recurrence

preoperative demographics, blood markers, surgical pathology information，and enhanced CT features.

Intervention Type OTHER

preoperative demographics, blood markers, surgical pathology information，and enhanced CT features.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

preoperative demographics, blood markers, surgical pathology information，and enhanced CT features.

preoperative demographics, blood markers, surgical pathology information，and enhanced CT features.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have the results of enhanced CT examination of the pancreas within 1 month before surgery in our hospital;
* Radical resection of pancreatic cancer was performed in our hospital;
* There are follow-up results in our hospital, and the follow-up endpoints include disease recurrence or at least 12 months.
* Complete clinical medical records and imaging data.

Exclusion Criteria

* non-R0 resection;
* Combined with other malignant tumors
* The patient's imaging data has technical problems or the lesion is too small (less than 1cm), which is not suitable for omics analysis.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Luo Cong

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Luo Cong

Deputy Director

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Zhejiang Province Cancer Hospital

Hangzhou, Zhejiang, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Zhejiang CH

Identifier Type: -

Identifier Source: org_study_id